Business / Finance

RSS

DaVita enhances company's governance policies and practices

The Board of Directors of DaVita Inc. today announced that it has enhanced the company's already strong corporate governance policies and practices.

14 Mar 2011

UnitedHealth Group ranked No. 1 on FORTUNE's 2011 'World's Most Admired Companies'

Diversified health and well-being company UnitedHealth Group earned the top overall ranking among insurance and managed care companies in FORTUNE's 2011 "World's Most Admired Companies" list, featured in the magazine's March 21 issue.

11 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Verenium repurchases $28.4 million in outstanding convertible notes

Verenium Corporation, a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it repurchased $28.4 million in principal amount of its outstanding convertible notes in a series of privately-negotiated transactions.

11 Mar 2011

Bill Gates and Schrödinger co-founder invest in Nimbus to advance large B-cell lymphoma programs

Nimbus Discovery LLC, a biopharmaceutical company using state-of the-art computational technology to discover novel medicines against exciting but difficult-to-drug disease targets, today announced an extension of its seed round with an investment by Bill Gates and Dr. Richard Friesner, the co-founder of Schrödinger and Professor of Chemistry at Columbia University. Atlas Venture, the founding investor, also participated.

11 Mar 2011

Hooper Holmes fourth quarter consolidated revenues decline 4% to $43.4 million

Hooper Holmes today announced financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Response Biomedical 2010 total revenues decrease to $7,610,827

Response Biomedical Corporation reported that it recorded total revenues of $7,610,827 compared to $9,946,269 in 2009 and reduced operating expenses by 13% to $9,216,257 in 2010 from $10,602,954 in 2009.

11 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010.

11 Mar 2011

Arena fourth quarter net loss decreases to $28.2 million

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

11 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

BioScrip fourth quarter revenue increases 31.9% to $450.4 million

BioScrip, Inc. today announced 2010 fourth quarter and year-end financial results. Fourth quarter revenue was $450.4 million with a net loss of $67.1 million, or $1.25 per share, which included a deferred-tax asset valuation allowance expense of $54.0 million and $9.2 million of litigation, restructuring, integration, acquisition, severance and CAP bad debt expense.

11 Mar 2011